InceptionR’s Alnylam Pharmaceuticals ALNY Stock Holding History

InceptionR’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,415	Closed	-$960K	–	637
2025 Q4	$960K	Sell	2,415 -1,104	-31%	-$489K	0.27%	117
2025 Q3	$1.6M	Sell	3,519 -1,057	-23%	-$430K	0.39%	36
2025 Q2	$1.49M	Buy	4,576 +3,238	+242%	+$896K	0.35%	68
2025 Q1	$361K	Buy	+1,338	New	+$344K	0.11%	342
2024 Q4	–	Sell	-1,224	Closed	-$337K	–	605
2024 Q3	$337K	Sell	1,224 -4,173	-77%	-$1.09M	0.08%	425
2024 Q2	$1.31M	Buy	+5,397	New	+$852K	0.37%	65
2023 Q3	–	Sell	-1,279	Closed	-$243K	–	390
2023 Q2	$243K	Buy	+1,279	New	+$254K	0.13%	318

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

InceptionR's ALNY Position: Q1 2026 in Review

InceptionR sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 2,415 shares — an estimated $960K sold.

InceptionR first reported a position in ALNY in Q2 2023 and held it in 7 quarters. The position peaked at $1.6M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

InceptionR reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
InceptionR sold 2,415 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $960K.
InceptionR first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 7 quarters.
InceptionR's Alnylam Pharmaceuticals position peaked at $1.6M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on InceptionR's 13F filing for Q1 2026, filed 14 May 2026.